Steven Bellon
Direttore Tecnico/Scientifico/R&S presso FOGHORN THERAPEUTICS INC.
Patrimonio netto: 1 M $ in data 31/05/2024
Posizioni attive di Steven Bellon
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| FOGHORN THERAPEUTICS INC. | Direttore Tecnico/Scientifico/R&S | 10/01/2022 | - |
| Corporate Officer/Principal | 01/06/2016 | 10/01/2022 |
Storia della carriera di Steven Bellon
Precedenti posizioni note di Steven Bellon
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 01/09/2008 | 01/05/2016 |
| Corporate Officer/Principal | 01/09/2008 | 01/05/2016 |
Formazione di Steven Bellon
| Haverford College | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| FOGHORN THERAPEUTICS INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Steven Bellon
- Esperienza
